Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Bonviva opvejer risiciene til behandling og forebyggelse af osteoporose hos kvinder efter overgangsalderen med forhøjet risiko for brud.
The Committee for Medicinal Products for Human Use (CHMP) decided that Bonviva’ s benefits are greater than its risks for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.